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Abstract Hepatitis C virus (HCV) is a highly variable pathogen that frequently establishes
chronic infection. This genetic variability is affected by the adaptive immune response but the
contribution of other host factors is unclear. Here, we examined the role played by interferon
lambda-4 (IFN-l4) on HCV diversity; IFN-l4 plays a crucial role in spontaneous clearance or
establishment of chronicity following acute infection. We performed viral genome-wide association
studies using human and viral data from 485 patients of white ancestry infected with HCV
genotype 3a. We demonstrate that combinations of host genetic variants, which determine IFN-l4
protein production and activity, influence amino acid variation across the viral polyprotein - not
restricted to specific viral proteins or HLA restricted epitopes - and modulate viral load. We also
observed an association with viral di-nucleotide proportions. These results support a direct role for
IFN-l4 in exerting selective pressure across the viral genome, possibly by a novel mechanism.
DOI: https://doi.org/10.7554/eLife.42463.001
Introduction
Hepatitis C virus (HCV) infects an estimated 71 million people worldwide (World Health Organiza-
tion, 2017) and can lead to severe liver disease in chronically infected patients. The virus is highly
variable and has been classified into seven distinct genotypes, and further divided into 67 subtypes,
based on nucleotide sequence diversity (Simmonds, 2004). The factors that have driven the evolu-
tionary path of HCV are multifactorial but undoubtedly are also shaped by host genetics. Because of
its major health burden, determining how both host and viral genetics contribute to the outcomes of
infection is critical for a better understanding of HCV-mediated pathogenesis (Ploss and Dubuisson,
2012) and the immune response to viral infection.
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Using a systematic genome-to-genome approach in a cohort of chronically infected patients, we
recently reported associations between an intronic single nucleotide polymorphism (SNP)
rs12979860 in the interferon lambda 4 (IFNL4) gene (CC vs. non-CC) and 11 amino acid polymor-
phisms on the HCV polyprotein (Ansari et al., 2017) at a 5% false discovery rate
(FDR) (Benjamini and Hochberg, 1995). This observation was unexpected since IFNL4 is a member
of the type III interferon (IFN-l) family that act as cytokines as part of the innate immune system and
therefore lack apparent epitope specificity (Bruening et al., 2017). These associations between poly-
morphisms on the HCV polyprotein and host IFNL4 SNP rs12979860 genotypes are further intriguing
given that variants within the IFNL4 locus (including SNP rs12979860) contribute to HCV clinical and
biological outcomes, including spontaneous virus clearance, response to IFN-based treatment, viral
load and liver disease progression (Aoki et al., 2015; Ge et al., 2009; Noureddin et al., 2013;
Patin et al., 2012; Rauch et al., 2010; Suppiah et al., 2009; Tanaka et al., 2009; Thomas et al.,
2009). It is possible that the associations between the outcomes of HCV infection and the IFNL4
locus are directly linked to its impact on the viral genome and the encoded polyprotein.
The intronic IFNL4 SNP rs12979860 is in high linkage disequilibrium with other SNPs that may be
more biologically relevant, including the exonic dinucleotide variant rs368234815 (r2 = 0.975 CEU
population, 1000 Genomes dataset) in IFNL4. This variant [DG > TT] causes a frameshift, abrogating
production of functional IFN-l4 protein (Prokunina-Olsson et al., 2013). Moreover, several amino
acid substitutions within IFN-l4 have been shown to alter its antiviral activity (Bamford et al., 2018;
Terczyn´ska-Dyla et al., 2014). In particular, a common amino acid substitution (coded by the SNP
rs117648444 [G > A]) in the IFN-l4 protein, which changes a proline residue at position 70 (P70) to a
serine residue (S70), reduces its antiviral activity in vitro (Terczyn´ska-Dyla et al., 2014). Thus, the
combination of alleles at rs368234815 and rs117648444 creates four potential haplotypes, two that
do not produce IFN-l4 protein (TT/G or TT/A; IFN-l4-Null) and two that result in production of two
IFN-l4 protein variants (DG/G; IFN-l4-P70 and DG/A; IFN-l4-S70). Patients harbouring the impaired
IFN-l4-S70 variant display lower hepatic interferon-stimulated gene (ISG) expression levels, which is
associated with increased viral clearance following acute infection and a better response to IFN-
based therapy, compared to patients carrying the more active IFN-l4-P70 variant (Eslam et al.,
2017).
In this study, we report a large number of associations between HCV-encoded amino acids across
the viral polyprotein and host IFNL4 SNP rs12979860, with 42 significant associations at a 5% FDR,
increasing to 76 viral sites at a 10% FDR. The associations are observed in both structural and non-
structural viral proteins and no enrichment of association signals is observed in any of the viral pro-
teins or HLA restricted epitope regions. We also find an association with viral nucleotide content
and certain dinucleotide frequencies, such as UpA (uracil base followed by adenine base). Finally, we
demonstrate that IFNL4 haplotypes coding for IFN-l4-S70 and IFN-l4-P70 variants differ in terms of
their impact on viral load and viral amino acid polymorphisms, in agreement with the reduced antivi-
ral activity of IFN-l4-S70. Together these observations suggest that IFN-l4 is a driver of HCV
sequence diversity and modulator of viral load.
Results
Host and virus genetic structures
To ensure that host and virus population structures had a minimal impact on our results, we used
paired genome-wide human and viral genetic data in a homogenous group of 485 patients with self
reported white ancestry, infected with HCV genotype 3a from two cohorts [BOSON (Foster et al.,
2015) and Expanded Access Program (EAP) (Foster et al., 2016) cohorts, NBOSON = 411,
NEAP = 74, see Supplementary file 1 and Materials and methods for a description of the cohorts].
To control for both human and virus population structures, we performed principal component anal-
ysis (PCA) on each of the host and viral genetic data (Materials and methods). The host PCA defined
a largely homogenous group corresponding to self-reported white ancestry (Figure 1—figure sup-
plement 1a). The first and second viral principal components (PCs) explained around 3% and 2% of
variance in HCV nucleotide diversity respectively (Figure 1—figure supplement 1b), indicating a
homogenous group of isolates as observed by the long terminal and short internal branches of the
phylogenetic tree (Figure 1—figure supplement 2a). The viral sequences from the two cohorts
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were non-randomly distributed on the tree as one clade was underrepresented in the EAP cohort
sequences; this clade corresponded to isolates in the BOSON cohort from outside the United King-
dom (treeBreaker Bayes factor = 249, see Materials and methods for an explanation on how to inter-
pret Bayes factor and Figure 1—figure supplement 3a). This observation was not reflected in host
IFNL4 SNP rs12979860 genotypes, which were randomly distributed on the viral phylogenetic tree
(treeBreaker Bayes factor = 1.1, Figure 1—figure supplement 3b). However, we did observe associ-
ations between the host IFNL4 SNP rs12979860 and the fifth and seventh viral PCs (p=1.310 15
and 7.2  10 9, respectively), which were not directed by host-virus population co-structuring, sug-
gesting that the IFNL4 locus drives HCV nucleotide diversity (Figure 1—figure supplement 2b–d
and Appendix 1).
The IFNL4 locus affects virus-encoded amino acids at specific sites
across the HCV polyprotein
A major advantage of determining entire HCV genomic sequence data is the possibility to perform
footprinting analysis at a genome-wide scale. The nucleotide and amino acid frequencies at poly-
morphic viral sites in the two cohorts were similar and no systematic differences were observed (Fig-
ure 1—figure supplement 4). We used logistic regression to test for association between IFNL4
SNP rs12979860 genotypes (CC vs. non-CC) and virus-encoded amino acids, including the first two
viral PCs and the first three host PCs as covariates to account for host-virus population co-structur-
ing. Presence or absence of each viral amino acid was used as the response variable; 977 tests were
performed at 471 viral sites. To test for possible confounders we separately added each of the cir-
rhosis status of patients, cohorts (BOSON vs. EAP), gender and age to the model as covariates.
These covariates were not associated with any specific amino acids at a 10% FDR (data not shown).
At a 5% FDR, 42 of the viral sites tested were associated with IFNL4 SNP rs12979860, increasing
to 76 sites at a 10% FDR (Figure 1 and Supplementary file 2). This represented 1.4% at a 5% FDR
and 2.5% at a 10% FDR of all the viral amino acids in the HCV genotype 3a polyprotein (N = 3021),
reflecting a large impact of the host IFNL4 locus on the amino acids encoded at variable sites on the
viral polyprotein. The most associated viral site was at position 2570 in the NS5B protein
(p=1.3210 8, log(OR)=1.19), as previously reported (Ansari et al., 2017). Notably, 26 of the 76
sites (34%) associated with the IFNL4 SNP rs12979860 at a 10% FDR lie within the HCV E2 glycopro-
tein (Appendix 1 and Figure 1—figure supplement 5). However, we did not observe significantly
enhanced enrichment or depletion for association signals in any specific viral protein, or in previously
reported HLA restricted epitope regions in HCV genotype 3a (von Delft et al., 2016)
(Supplementary file 3 and Materials and methods).
To ensure that host-virus population co-structuring or some other systematic bias was not con-
founding our results, we performed the same tests against the HCV amino acids for 500 host SNPs
from across the human genome with a minor allele frequency (MAF) similar to IFNL4 SNP
rs12979860 MAF, further referred to as ‘the 500 frequency-matched SNPs’. In effect we performed
500 viral GWASs, one for each of the 500 frequency-matched SNPs. Using a 5% FDR (calculated
independently for each of the 500 viral GWASs), we observed no significant associations for 491 of
the host SNPs tested against the HCV polyprotein. The remaining nine host SNPs were associated
with one HCV amino acid each (Supplementary file 4). However, these associations are likely to be
false positives as multiple testing corrections were performed for each viral GWAS independently.
Additionally, the distribution of P-values for the association tests between HCV amino acids and the
500 frequency-matched SNPs followed the null distribution of no associations (Figure 1—figure sup-
plement 6a), confirming that there was no systematic bias in our analysis. By comparison, the distri-
bution of the P-values for the association tests between HCV amino acids and IFNL4 SNP
rs12979860 deviated from the null distribution of no associations. This observation and the large
number of HCV amino acids significantly associated with IFNL4 SNP rs12979860 genotypes
highlighted that the broad impact of the IFNL4 locus on HCV-encoded amino acids was authentic
and not driven by host-virus population co-structuring.
We then explored nucleotide sequences at the codon level to distinguish the impact of the IFNL4
SNP rs12979860 on viral nucleotides as distinct from its effect on viral amino acids. We tested for
associations between host IFNL4 SNP rs12979860 and HCV codon changes from the most common
codon to synonymous and non-synonymous codons (Materials and methods). For each HCV codon
site with at least 20 synonymous and 20 non-synonymous codons (N = 348), we performed a logistic
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regression including the first two viral PCs and the first three host PCs to test for association
between IFNL4 SNP rs12979860 (and the 500 frequency-matched SNPs as in the previous section)
and changes from the most common codon to synonymous and non-synonymous codons
(Materials and methods). We observed that non-synonymous changes at 16 viral codons were signifi-
cantly associated with IFNL4 SNP rs12979860 at a 5% FDR, increasing to 35 viral codons at a 10%
FDR (Supplementary file 5). As expected the 500 frequency-matched SNPs did not show the same
level of associations with HCV non-synonymous codon changes (Figure 1—figure supplement 6b).
Figure 1. HCV genome-wide association study with IFNL4 SNP rs12979860 genotypes (CC vs. non-CC). (a) Manhattan plot. The dashed line indicates
5% FDR. At this level 42 sites on the virus polyprotein are significantly associated with IFNL4 SNP. (b) Schematic of the HCV polyprotein.
DOI: https://doi.org/10.7554/eLife.42463.002
The following figure supplements are available for figure 1:
Figure supplement 1. Host and viral principal components.
DOI: https://doi.org/10.7554/eLife.42463.003
Figure supplement 2. Association between viral PCs and IFNL4 SNP rs12979860 genotypes in the combined cohort (N = 485).
DOI: https://doi.org/10.7554/eLife.42463.004
Figure supplement 3. Distribution of (a) cohort from which the sequences were obtained (BOSON N = 411 or EAP N = 74) and (b) host IFNL4 SNP
rs12979860 genotypes (CC or non-CC) on the virus phylogenetic tree.
DOI: https://doi.org/10.7554/eLife.42463.005
Figure supplement 4. Viral allele frequencies in the BOSON (N = 411) and EAP (N = 74) cohorts.
DOI: https://doi.org/10.7554/eLife.42463.006
Figure supplement 5. IFNL4-associated residues on the core E2 structure.
DOI: https://doi.org/10.7554/eLife.42463.007
Figure supplement 6. QQ-plots for association studies between viral amino acids and viral codons and host IFNL4 SNP rs12979860 and 500 host SNPs
chosen across the human genome with a minor allele frequency (MAF) similar to the IFNL4 SNP rs12979860 MAF.
DOI: https://doi.org/10.7554/eLife.42463.008
Figure supplement 7. Effect size (beta) of IFNL4 SNP rs12979860 genotypes (CC vs. non-CC) on the proportion of dinucleotide frequencies in the
combined cohort (N = 485).
DOI: https://doi.org/10.7554/eLife.42463.009
Figure supplement 8. Effect size (beta) of IFNL4 SNP rs12979860 genotypes (CC vs. non-CC) on the proportion of dinucleotide frequencies in the
BOSON (N = 411) and EAP (N = 74) cohorts.
DOI: https://doi.org/10.7554/eLife.42463.010
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We also observed that synonymous changes at two viral codons were significantly associated with
IFNL4 SNP rs12979860 at a 5% FDR, increasing to four viral codons at a 10% FDR
(Supplementary file 6 and Figure 1—figure supplement 6c). This indicates that the effect of the
IFNL4 locus on virus sequence diversity is mostly at the amino acid level, although a small impact on
nucleotide substitutions cannot be excluded.
We hypothesised that the observed impact of IFNL4 SNP rs12979860 on viral nucleotide sequen-
ces might be induced through dinucleotide sensing mechanisms. Most viruses suppress genomic
CpG and UpA dinucleotide frequencies, supposedly to mimic host mRNA composition and avoid
the immune response (Simmonds et al., 2013). To explore this possibility, we tested the association
between the dinucleotide frequencies in each viral sequence and the host IFNL4 SNP rs12979860
(Materials and methods). The viral UpA dinucleotide frequency (estimated as the ratio of observed
to expected frequencies) was significantly lower in the host individuals with IFNL4 SNP rs12979860
non-CC group compared to the CC group (p=1.510 6, Figure 1—figure supplement 7). By con-
trast, the viral UpG dinucleotide frequency was significantly higher in the IFNL4 SNP rs12979860
non-CC group compared to the CC group (p=1.510 5). The viral CpC and CpA dinucleotide fre-
quencies were also significantly different between the individuals with IFNL4 SNP rs12979860 CC
and non-CC genotypes (p=3.310 4 and p=3.310 4, respectively). Similar results were observed
by analysing the cohorts independently (Appendix 1 and Figure 1—figure supplement 8).
IFN-l4 protein impacts on viral amino acid variation and viral load
We then investigated the impact of the different haplotypes of IFNL4 on HCV amino acid diversity
and viral load to refine its possible role. After imputing and phasing IFNL4 rs368234815 and
rs117648444 (Materials and methods), we observed three haplotypes: TT/G (IFN-l4-Null); DG/G
(IFN-l4-P70) and DG/A (IFN-l4-S70). HCV-infected patients were classified into three groups accord-
ing to their predicted ability to produce IFN-l4 protein: (i) no IFN-l4 (two allelic copies of IFN-l4-
Null, NBOSON = 145, NEAP = 41), (ii) IFN-l4–S70 (two copies of IFN-l4-S70 or one copy of IFN-l4-
S70 and one copy of IFN-l4-Null, NBOSON = 48, NEAP = 7), and (iii) IFN-l4-P70 (at least one copy of
IFN-l4-P70, NBOSON = 218, NEAP = 26) (Supplementary file 7).
Since IFN-l4-S70 can be distinguished phenotypically from IFN-l4-P70 both in vivo and in vitro,
we examined whether the IFNL4 haplotypes had distinct effects on viral amino acid polymorphisms
and viral load. We estimated the effect size of IFN-l4-S70 and IFN-l4-P70 relative to the IFN-l4-
Null haplotype on the presence and absence of the 76 amino acids associated with IFNL4 SNP
rs12979860 genotypes at a 10% FDR. We found that the estimated effect sizes of IFN-l4-S70 were
consistently smaller than those for IFN-l4-P70 (Figure 2). Under the null hypothesis that there is no
difference in the effect sizes of IFN-l4-P70 and IFN-l4-S70 variants on viral amino acid polymor-
phisms, we would expect the slope of the linear regression line (Figure 2) to have a value of one.
However, the estimated slope of the best-fit line was significantly different from one (slope = 0.77,
p=9.610 7, Figure 2). Additionally, we used bootstrapping to account for the uncertainty associ-
ated with the estimated effect sizes of IFN-l4-P70 and IFN-l4-S70 variants on HCV amino acid poly-
morphisms (Materials and methods). When estimating the slope of the line, we observed that the
bootstrap 95% confidence interval [0.69, 0.99] for the slope of the line did not include one. Thus, we
concluded that the impact of the host IFN-l4-S70 variant on HCV-encoded amino acids was signifi-
cantly smaller than the IFN-l4-P70 variant.
We then investigated the effects of IFN-l4 haplotypes on viral load. For this analysis, the EAP
cohort was excluded as these patients had advanced liver disease with consistently lower viral loads
relative to the BOSON cohort (Figure 3—figure supplement 1). We observed no difference in
mean viral load between patients carrying IFN-l4-S70 and IFN-l4-Null haplotypes (p=0.61). How-
ever, the viral load in patients carrying IFN-l4-P70 was significantly lower than in the other two
groups (PIFN-l4-S70 = 1.610
 4 and PIFN-l4-Null = 3.910
 10), with IFN-l4-P70 conferring an approxi-
mately 2.3-fold decrease in viral load compared to IFN-l4-S70 (mean for IFN-l4-P70 = 2,905,333,
IFN-l4-S70 = 6,703,875 and IFN-l4-Null = 6,256,523 IU/ml, Figure 3a).
We used a Bayesian approach to investigate the relationship between the effect sizes of the three
IFN-l4 haplotypes on viral load (Figure 3b). In essence, this method weighs up the evidence that
the genetic effects of the IFN-l4-Null, IFN-l4-S70 and IFN-l4-P70 haplotypes are the same or not
relative to each other (Materials and methods). We tested five models; the effects of the three
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haplotypes are identical (model 1), the effects of IFN-l4-P70 and IFN-l4-Null are identical and differ-
ent from the effect of IFN-l4-S70 (model 2), the effects of IFN-l4-S70 and IFN-l4-Null are identical
and different from the effect of IFN-l4-P70 (model 3), all three haplotypes have different effect sizes
(model 4) and the effects of IFN-l4-P70 and IFN-l4-S70 are the same but different from the effect
of IFN-l4-Null haplotype (model 5). Equal prior probabilities were used for all models. Model 3 had
the highest posterior probability of 0.82 (Figure 3b).
We had previously reported an association between IFNL4 SNP rs12979860 genotypes, the HCV-
encoded amino acids at position 2414 in the polyprotein and viral load (Ansari et al., 2017). In the
present study, we further stratified the analysis by IFNL4 haplotypes. The viral serine (S) residue at
site 2414 (S2414) was significantly enriched in patients coding for the IFN-l4-P70 variant compared
to IFN-l4-S70 (p=3.3910 03) and IFN-l4-Null (p=5.9410 09) coding patients. S2414 was present
in 86% (211/244) of IFN-l4-P70 carrying patients, 69% (38/55) of IFN-l4-S70 carrying patients and
62% (114/185) of IFN-l4-Null carrying patients. In HCV-infected patients with a serine residue at
position 2414, we observed no significant difference in mean viral load between IFN-l4-Null and
IFN-l4-S70 carriers (p=0.31, Figure 3c), but both groups had a significantly higher viral load than
IFN-l4-P70 carriers (pIFN-l4-Null=2.7x10
 9; pIFN-l4-S70=1.6x10
 10). However, no such association
(p=0.49) was found in HCV-infected patients with a non-serine residue at this site (Figure 3c). We
performed a Bayesian analysis that compared 58 possible models against each other (from all effect
sizes being the same to all being different from each other). The model where only the ‘IFN-l4-P70
+ S2414’ group had an effect size different from the other groups (model 5) had the highest poste-
rior probability of 0.33 (Figure 3d and Appendix1). Taken together, the combination of IFN-l4-P70
Figure 2. Comparison of the effect sizes (log(OR)) of host IFN-l4 variants (IFN-l4-S70 and IFN-l4-P70 relative to IFN-l4-Null) on HCV-encoded amino
acids. The circles show the log(OR) estimates and the grey lines indicate the 95% confidence intervals. The dashed line is the y = x line which has a
slope of one. The solid black line shows the linear regression line, which has a slope of 0.77 that is significantly different from one (y = x line,
p=9.610 7).
DOI: https://doi.org/10.7554/eLife.42463.011
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and S2414 conferred a 2.6-fold decrease in viral load compared to IFN-l4-S70 and S2414 (mean viral
load for IFN-l4-P70 and S2414 = 2,376,747 IU/ml, and mean viral load IFN-l4-S70 and
S2414 = 6,093,167 IU/ml).
Discussion
Here, we show that genetic variants in the human IFNL4 locus drive widespread sequence changes
across the entire HCV polyprotein - much larger than we previously reported (Ansari et al., 2017).
We did not observe statistically significant enrichment of association signals in any specific HCV pro-
tein nor in HLA restricted epitope regions. This indicates that the host IFNL4 locus, and hence the
innate immune response, can influence the amino acid residues that are encoded at specific sites on
the HCV polyprotein. The mechanism of action of IFN-l4 in determining such selectivity is not
Figure 3. Bayesian model comparison of effect sizes of IFNL-l4 variants on viral load in the BOSON cohort (N = 411). (a) Pretreatment viral load
stratified by the host IFN-l4 variants. The black dots and lines indicate the mean and 95% confidence interval (CI) for each group. (b) The posterior
probability of the five tested models from (a) stacked on top of each other (from model 1 to model 5; posterior probabilities of models 1, 2 and 5 are
too small to be labelled on this plot). Models where the posterior probability is higher or lower than the prior probability are coloured as dark grey and
light grey respectively. Only model 3 (as indicated) has a posterior probability bigger than its prior probability and it assumes that the mean viral load is
identical in IFN-l4-Null and IFN-l4-S70 groups and different from the mean viral load of IFN-l4-P70 group. (c) Viral load stratified by the host IFNL-l4
variants and the presence and absence of serine at the viral amino acid site 2414. The black dots and lines indicate the mean and 95% CI for each
group. (d) The posterior probability of the 58 tested models from (c) stacked on top of each other (from model 1 to model 58; only models where the
posterior probability is higher than the prior probability are labelled on this plot). Models where the posterior probability is higher or lower than the
prior probability are coloured as dark grey and light grey respectively. Model 5 has the highest posterior probability and it assumes that the mean viral
load is only different in ‘IFN-l4-P70 + 2414 serine’ group and identical in other groups.
DOI: https://doi.org/10.7554/eLife.42463.012
The following figure supplement is available for figure 3:
Figure supplement 1. Pre-treatment viral load stratified by cohort.
DOI: https://doi.org/10.7554/eLife.42463.013
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known. We also report an association of the IFNL4 locus with synonymous codon variants, suggest-
ing that this locus might also affect the HCV genome at the nucleotide sequence level. Finally, we
report that the IFNL4 haplotype coding for the IFN-l4-S70 variant has a smaller impact on viral load
and viral amino acid variation at associated sites compared to the haplotype coding for the more
active IFN-l4-P70 variant. This indicates that the IFNL4 gene not only mediates HCV amino acid vari-
ation but also modulates viral load in patients. Hence, our findings extend the association between
genetic variation in the IFNL4 locus and outcome of HCV infection as well as hepatic
disease (Aoki et al., 2015; Ge et al., 2009; Noureddin et al., 2013; Patin et al., 2012;
Rauch et al., 2010; Suppiah et al., 2009; Tanaka et al., 2009; Thomas et al., 2009; Eslam et al.,
2017).
We selected patients chronically infected with HCV genotype 3a and of self-reported white ances-
try to limit the impact of human and viral population co-structuring in our analyses. We observed
that 2.5% of HCV-encoded amino acids across the polyprotein were significantly associated with
host IFNL4 SNP at a 10% FDR. No such association was observed for 500 host SNPs chosen from
across the human genome with a MAF similar to that for IFNL4 SNP rs12979860. This indicated that
the observed impact of IFNL4 SNP rs12979860 on the viral sequences was not due to population
structure or other systematic bias. Compared to our previous report (Ansari et al., 2017), the num-
ber of sites associated with IFNL4 genotype increased from 11 to 42 at a 5% FDR. One of the 11
previously reported associations was not reproduced (position 2576) as it was not tested in this
study, due to more stringent frequency filtering (an amino acid had to be present in at least 20 sam-
ples to be tested). Thus, we have identified a further 32 associated sites at a 5% FDR compared to
our previous report. There are two key factors that have contributed to this increased number of
associated sites. Firstly, only HCV genotype 3a sequences found in those of white ancestry have
been included in the analysis; our previous report included HCV genotype 2 and other genotype 3
subtypes from a broader ethnic mix. Secondly, we have used logistic regression and accounted for
population structure by including viral and host genetic PCs as covariates in the analysis. This
approach has recently been shown to be more powerful to detect associations in genome-to-
genome analysis (Naret et al., 2018). Thus, focusing on a homogenous population (white ethnicity
infected with genotype 3a) and using logistic regression has increased the power of our study to
detect many more associations between the IFNL4 locus and amino acid variation in the HCV
polyprotein.
To distinguish the effect of IFNL4 SNP rs12979860 on viral amino acid variation from nucleotide
sequence variability, we investigated the association of the host IFNL4 SNP rs12979860 with synony-
mous and non-synonymous codon changes in the HCV genome. IFNL4 SNP rs12979860 genotypes
were associated with 35 non-synonymous codon changes at a 10% FDR, but we also observed four
significant associations with synonymous codon changes. This indicated that in addition to a wide-
spread impact at the amino acid level, the IFNL4 locus may also independently drive nucleotide
diversity but to a lesser extent.
To further explore the impact of the IFNL4 variants on HCV genomic sequences, we investigated
viral dinucleotide frequencies. The HCV UpA dinucleotide frequency was significantly associated
with the IFNL4 SNP rs12979860 genotypes; interestingly, ribonuclease L (RNase-L), an ISG that
cleaves viral RNA to control viral infections in animals (Ding and Voinnet, 2007), targets both UpA
and UpU dinucleotides (Wreschner et al., 1981). Moreover, HCV genotype 1, which is relatively
resistant to IFN-based therapy, has a lower frequency of UpA and UpU dinucleotides than the more
IFN-sensitive HCV genotypes 2 and 3 (Dao Thi et al., 2012; Kong et al., 2012). Indeed, the UpA
dinucleotide is targeted by RNA-degrading enzymes and its presence in a RNA sequence acceler-
ates its degradation in the cytoplasm (Simmonds et al., 2013). It is possible that the more stringent
immune environment of non-CC patients (with higher hepatic expression of ISGs) selects virus with a
lower UpA frequency. However, we note that the IFNL4 SNP rs12979860 non-CC patients have a
modest reduction (0.9%) in their viral UpA frequencies relative to the CC patients and that this
reduction could be mediated by the widespread amino acid changes associated with the IFNL4 SNP
rs12979860.
Previous studies have shown that IFN-l4-P70 and IFN-l4-S70 variants of IFN-l4 protein have dis-
tinct phenotypes, both in vivo and in vitro. We hypothesized that if IFN-l4 contributes to changes in
the viral polyprotein, then the IFN-l4-P70 and IFN-l4-S70 variants should have different effect sizes
on HCV-encoded amino acids and viral load. By imputing and phasing IFNL4 SNPs in our cohort, we
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inferred the haplotypes consisting of the IFNL4 rs368234815 (DG/TT) and rs117648444 (G/A) var-
iants. Using these data, we observed that the haplotype coding for the IFN-l4-S70 variant had a
smaller effect on viral amino acid variability compared to the haplotype coding for the IFN-l4-P70
variant. This observation agrees with previous independent studies showing the reduced antiviral
activity for IFN-l4-S70 in vitro (Bamford et al., 2018; Terczyn´ska-Dyla et al., 2014). Moreover, the
mean viral load in IFN-l4-Null carrying patients was similar to those carrying the IFN-l4-S70 variant;
by contrast, those carrying an IFN-l4-P70 variant had a reduced viral load, which correlates with its
higher antiviral activity. Taken together, these observations reinforce the hypothesis that IFNL4 is a
functional gene with a major role in HCV infection. We conclude that production of IFN-l4 protein
drives an altered immune response that mediates reduced viral load with a broad impact on viral
amino acid diversity.
In this study, we demonstrated by using paired host-HCV genomic data that host IFNL4 gene, a
cytokine that is part of the innate immune response and not expected to target specific viral resi-
dues, can mediate selection of amino acids at specific sites on the HCV polyprotein. We report that
1.4% (42/3021) of the HCV amino acids across the viral polyprotein are associated with host IFNL4
SNP rs12979860 at a 5% FDR and that the impact on amino acid variation is spread across all viral
proteins. In comparison, we previously reported that 0.7% of the HCV amino acids were associated
with HLA class I and II alleles (Ansari et al., 2017) at a 5% FDR. The only other major driver of HCV
amino acid variation is the host B cell response, which is largely restricted to modifying amino acids
in the envelope glycoproteins, in particular E2 (Ball et al., 2014). Thus, although both arms of the
adaptive immune system direct amino acid selection through pressure on epitopes recognised by T
and B cell responses to infection, our results show that the innate immune response also has the
capacity to drive particular polymorphisms in HCV-encoded proteins and that its impact is compara-
ble to that of the T cell response (as indicated by HCV amino acid variants associated with HLA
alleles).
Given that we did not observe any significant enhancement or depletion of association signals in
a specific viral protein or in HLA-restricted epitopes, IFN-l4 may exert its impact through a previ-
ously unknown mechanism or at more than one stage of the virus life cycle. We anticipate that this
would result from distinct host responses in those who carry genetic variants that lead to IFN-l4 syn-
thesis as compared to individuals who carry the pseudogenized form of the gene. In common with
other IFNs, IFN-l4 induces a large number of ISGs, many of which are largely unstudied or poorly
characterised. Within such an environment, it is possible that subtle selection of certain amino acids
along the polyprotein will provide an advantage for viral entry, RNA replication, virion assembly and
release.
Although there was no significant enrichment of associations comparing the structural with the
non-structural proteins, the E2 glycoprotein contained the highest proportion of sites affected by
IFNL4 SNP rs12979860. From mapping these sites onto previously known functional domains on E2,
we found that many residues were located either in hypervariable region 1 (HVR1) or on the surface
of the protein. Indeed, some sites coincided with epitopes that are targets for the antibody response
or have a role in virus entry (Appendix 1 and Figure 1—figure supplement 5). Since the host
response to HCV genotype 3a infection induces pathways including those affecting B cell
development (Robinson et al., 2015), we do not exclude the possibility that IFNL4 SNP rs12979860
genotype either influences B cell response to infection or the process of virus binding and entry.
Indeed, a recent report has demonstrated the emergence of variants in E2 during establishment of
chronic infection that give enhanced resistance to interferon-induced transmembrane (IFITM)
proteins (Wrensch et al., 2019). One of the E2 residues that encoded a different amino acid as
chronicity developed was at position 500, which is an IFNL4-associated site (Supplementary file 2).
Given that IFITM proteins potently inhibit virus entry, it is possible that differences in IFITM induction
between those who do and do not produce IFN-l4 may account for some of the footprint observed
in the E2 protein sequence. Moreover, IFITM proteins cooperate with anti-HCV neutralising antibod-
ies to enhance restriction of virus entry. Therefore, there may be interaction between genes differen-
tially regulated between IFN-l4 producers and non-producers and components of the adaptive
immune system, which together influence the amino acids encoded at certain IFNL4-associated
sites (Wrensch et al., 2019).
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To reduce any confounding effects due to population stratification, we limited our analysis to a
homogenous population of self-reported white origin infected with HCV genotype 3. Thus, our
observations cannot directly be extended to other human populations or other HCV genotypes. This
study provides a foundation for future analysis on whether IFNL4 genetic variation also drives diver-
sity in other HCV genotypes and subtypes across other ethnic populations (also see ‘Adaptation of
hepatitis C virus to interferon lambda polymorphism across multiple viral genotypes’ by Chaturvedi
et al. in this issue). Additionally, our observations were performed with in vivo data; further func-
tional studies using appropriate in vitro model systems are needed to understand how the IFNL4
locus drives HCV amino acid variation and modulates viral load. Such studies may also help to inform
the basis for diversity and evolution of HCV in the presence or absence of IFNL4.
There are now multiple studies suggesting that the IFNL3-IFNL4 locus could be a key player in
the defense against viruses other than HCV. In HIV-infected patients, the rs368234815 variant has
been associated with long-term non-progressor HIV-1 controllers (Dominguez-Molina et al., 2017).
In influenza virus infection, IFNL4 SNP rs8099917 was associated with increased sero-conversion after
influenza vaccination (Egli et al., 2014a). IFNL4 variants have also been associated with
bronchiolitis (Scagnolari et al., 2012), cytomegalovirus (Egli et al., 2014b) and Andes
virus (Angulo et al., 2015) infections. These observations suggest that IFNL4 possibly plays a role in
many viral infections and immune related diseases in the liver and other organs. Investigating how
IFN-l4 (a cytokine without epitope specificity) drives amino acid selectivity in the HCV polyprotein
would add a new dimension to how the human innate immune system interacts with viruses and con-
trols infectious diseases.
Materials and methods
Patient cohorts
For this study, we used patient data from the BOSON and EAP cohorts that have been described
elsewhere (Foster et al., 2015; Foster et al., 2016). All patients provided written informed consent
before undertaking any study-related procedures. The BOSON study protocol was approved by
each institution’s review board or ethics committee before study initiation. The study was conducted
in accordance with the International Conference on Harmonisation Good Clinical Practice Guidelines
and the Declaration of Helsinki (clinical trial registration number: NCT01962441). The EAP study con-
forms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by
the institution’s human research committee. The EAP patients were enrolled by consent into the
HCV Research UK registry. Ethics approval for HCV Research UK was given by NRES Committee
East Midlands - Derby 1 (Research Ethics Committee reference 11/EM/0314).
Patients from the BOSON cohort were recruited in five different countries (Australia, Canada,
New Zealand, United Kingdom and United States). Patients from the EAP cohort were recruited
exclusively in the United Kingdom.
To limit the potential impact of population structure, we restricted the analysis to patients of self-
reported white ancestry infected with HCV genotype 3a for which we had obtained both host
genome-wide SNP data and full-length HCV genome sequences. In total we included 485 patients in
the study, 411 from the BOSON cohort and 74 from the EAP cohort.
The majority of the patients from the BOSON cohort have no or mild liver disease (compensated
liver cirrhosis). The EAP cohort on the other hand consists of HCV-infected patients with advanced
liver disease, the majority of whom had decompensated cirrhosis.
Host genotyping and imputation
Informed consent for genetic analysis was obtained from all patients. Genomic DNA was extracted
from buffy coat using Maxwell RSC Buffy Coat DNA Kit (Promega) as per the manufacturer’s proto-
col and quantified using Qubit (Thermofisher). DNA samples from patients were genotyped using
the Affymetrix UK Biobank array, as described elsewhere (Ansari et al., 2017). Phasing and imputa-
tion was performed using SHAPEIT2 (Delaneau et al., 2013)Dao Thi et al., 2011 and
IMPUTE2 (Howie et al., 2009) version 2.3.1 using default settings and the 1000 Genomes Phase III
dataset as a reference population (Auton et al., 2015). Imputation quality was high for both
rs117648444 and rs368234815 variants (information 0.974 and 0.994 respectively and certainty 0.995
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and 0.997 respectively). Patients from the EAP cohort from whom enough DNA was available (62/
74) were also independently genotyped for both rs117648444 and rs368234815 variants. Genotyp-
ing of IFNL4 rs368234815 and rs117648444 was performed on DNA using the TaqMan SNP geno-
typing assay and sequences described previously (Prokunina-Olsson et al., 2013) with Type-it Fast
SNP Probe PCR Master Mix (Qiagen). The concordance between genotyped and imputed genotypes
was 100% for both variants.
Virus sequencing
The generation and assembly of viral sequences from HCV-infected clinical samples for the BOSON
and EAP cohorts have been described previously (Ansari et al., 2017; Singer et al., 2019).
Statistical analysis
Human and viral population structure
For the viral data, principal component analysis (PCA) was performed on the nucleotide data as fol-
lows. The presence and absence of each viral nucleotide at all variable sites in the alignment was
coded as a binary variable such that a bi-allelic site on the viral genome was converted into two
binary variables (one for each nucleotide), a tri-allelic site into three binary variables and a quad-alle-
lic site into four binary variables. R (version 3.4.3, https://www.r-project.org) was then used to per-
form the PCA using the prcomp function with default settings. PCA was performed using
flashpca (Abraham and Inouye, 2014) for human genotype data.
Whole-genome viral consensus sequences for each patient were aligned using
MAFFT (Katoh and Standley, 2013) with default settings. This alignment was used to create a maxi-
mum-likelihood tree using RAxML (Stamatakis, 2014), assuming a general time-reversible model of
nucleotide substitution under the gamma model of rate heterogeneity. The resulting tree was rooted
at midpoint.
We used treeBreaker software (Ansari and Didelot, 2016) (https://github.com/ansariazim/tree-
Breaker) to measure the association between the virus phylogenetic tree and the host IFNL4 SNP (CC
vs. non-CC) and with the cohort from which the viral sequence was obtained (BOSON vs. EAP). This
software uses a Bayesian model to infer whether the phenotype of interest is randomly distributed on
the tips of the tree and to estimate which clades, if any, have a distinct distribution of the phenotype
of interest from the rest of the tree. This software also performs Bayesian model comparison. It pro-
vides a Bayes factor for the alternative model (there is at least one or more branches with distinct dis-
tribution of the phenotype of interest) to the null model (there are no branches with distinct
phenotype distribution on the tree). Bayes factor is a summary of the evidence provided by the data in
favour of one model compared to another. In other words, the higher the Bayes factor, the more sup-
port there is for one model against another. Assuming that we are testing an alternative model against
a null model, it has been suggested that the Bayes factor can be divided into four categories
(Kass and Raftery, 1995). Bayes factor: 1 to 3.2, very little evidence against the null model. Bayes fac-
tor: 3.2 to 10, substantial evidence against null model and in favour of the alternative model. Bayes fac-
tor: 10 to 100, strong evidence against null model and in favour of the alternative model. Bayes factor:
>100, decisive evidence against null model and in favour of the alternative model.
Association tests
The univariate association between the IFNL4 SNP rs12979860 (CC vs. non-CC) and the viral PCs
was tested using logistic regression in R. We used the qvalue function from the qvalue package in R
to perform the FDR analysis.
To choose 500 SNPs across the human genome with minor allele frequency (MAF) similar to the
IFNL4 SNP rs12979860 MAF, we used Fisher’s exact test to compare all SNPs against the IFNL4 SNP
rs12979860 (2  3 contingency table where the columns indicate the number of 0, 1 and 2 copies of
the minor allele and the rows indicate the IFNL4 SNP and the target SNP counts) and chose the 500
SNPs with the largest P-values (least significance). SNPs in the IFNL3-IFNL4 region were not
included.
To test for association between the virus amino acids and the host SNPs we used logistic regression
in R including as covariates the first three host and the first two viral PCs. We investigated presence
and absence of each amino acid at all variable sites, given that the amino acid was present in at least
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20 HCV sequences in our dataset. The presence and absence of the viral amino acid was used as the
response variable and the host SNP coded as 0 (homozygous for major alleles) and 1 (all other geno-
types) as the explanatory variable (the same coding as the IFNL4 SNP rs12979860 CC vs. non-CC).
To test for enrichment or depletion of the association signals in a viral protein or the epitope
regions, we used Fisher’s exact test. Each tested site is either within the target region or not and it
is either classified as significant or not. The resulting 2  2 contingency table was tested using fisher.
test function in R.
Codon level analysis
To separate the impact of the IFNL4 SNP rs12979860 on amino acids from nucleotides we investi-
gated the nucleotide sequences at the codon level. At each codon site (where the most common
codon had at least 20 synonymous and 20 non-synonymous codons) we used logistic regression to
test for association between IFNL4 SNP rs12979860 (CC vs. non-CC) and the changes from the most
common codon to synonymous and non-synonymous codons. The IFNL4 SNP rs12979860 was
denoted as the response variable and the codons were used as a categorical explanatory variable
with three levels. The effect sizes (log(OR)) and P-values were estimated for the synonymous and
non-synonymous codons relative to the most common codon. We included the first two viral PCs
and the first three host PCs as covariates in this analysis.
Di-nucleotides analysis
To estimate the viral dinucleotide frequencies, the observed proportion of each dinucleotide was
normalised by its expected proportion (assuming the nucleotides are independent the expected pro-
portion can be calculated by multiplying the observed proportions for the relevant nucleotides). To
test for association with IFNL4 SNP rs12979860 genotype we used a linear regression where the nor-
malised dinucleotide proportions were used as the response variable and the IFNL4 SNP
rs12979860 genotype as a categorical explanatory variable. We included the first two viral PCs and
the first three host PCs as covariates.
Effect of the three IFN-l4 protein variants
To estimate the effect of the IFN-l4 protein variants on the encoded HCV amino acids, we used the
76 sites associated with IFNL4 SNP rs12979860 at a 10% FDR. HCV-infected patients were classified
into three groups according to their predicted ability to produce IFN-l4 protein: (i) no IFN-l4 (two
allelic copies of IFN-l4-Null, NBOSON = 145, NEAP = 41), (ii) IFN-l4–S70 (two copies of IFN-l4-S70 or
one copy of IFN-l4-S70 and one copy of IFN-l4-Null, NBOSON = 48, NEAP = 7), and (iii) IFN-l4-P70
(at least one copy of IFN-l4-P70, NBOSON = 218, NEAP = 26). We then used logistic regression to
estimate the effect sizes (log(OR)) for IFN-l4-P70 and IFN-l4-S70 on the virus amino acids relative to
IFN-l4-Null. The presence and absence of the reported viral amino acid was used as the response
variable and the host IFN-l4 status was used as the explanatory variable with the IFN-l4-Null used
as the base level and the log(OR) for IFN-l4-P70 and IFN-l4-S70 were estimated relative to the IFN-
l4-Null base level. We included the first two viral PCs and the first three host PCs as covariates to
account for host-virus populations co-structuring.
To test whether the effect sizes of IFN-l4-P70 and IFN-l4-S70 on viral amino acids are the same,
we used the above estimated effect sizes and fitted a linear regression line to it. One viral site (position
2371) was excluded from this analysis as it had unreliable effect size estimate (log(OR) =  17) for IFN-l
4-S70 variant. Under the null hypothesis that IFN-l4-P70 and IFN-l4-S70 have the same effect sizes,
we would expect that the linear regression line to have a slope of one. To test whether the slope of the
fitted line is different from one, we used R to fit a linear regression line with intercept of zero. We used
bootstrapping to account for the uncertainty associated with the estimated effect sizes of IFN-l4-P70
and IFN-l4-S70 on viral amino acids. We simulated 10,000 bootstrap datasets where the effect sizes of
each IFN-l4 variant on each HCV amino acid were simulated using a normal distribution with mean set
to the estimated effect size of the variant on that HCV amino acid and standard deviation set to the
standard error of the estimate. For each dataset we fitted a linear regression with intercept of zero
and estimated the slope of the fit. The empirical bootstrap 95% confidence interval of the slope of the
line was estimated as [2* best_estimate_slope – 97.5%_quantile_of_bootstrap_slopes, 2*
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best_estimate_slope – 2.5%_quantile_of_bootstrap_slopes]. The ‘best_estimate_slope’ is the slope of
the line estimated from the effect sizes without accounting for uncertainty.
To assess whether the mean viral load was different in the three patient groups of IFN-l4-Null,
IFN-l4-P70 and IFN-l4-S70, we used a Bayesian framework to perform model comparison (see
Appendix 1 for further details). The models we considered comprised fixed and independent effects
between the IFN-l4 variants. We standardised the log10(viral load) so that it had a mean of zero
and standard deviation of one. We used linear regression to get maximum likelihood estimates of
the effects of IFN-l4-S70 and IFN-l4-P70 variants relative to the IFN-l4-Null variant. The estimates
were adjusted for cirrhosis status and population structure including the first two viral PCs and the
first three host PCs in the regression as covariates. For each effect size, we assumed a normally dis-
tributed prior on the log(OR) of association with mean of zero. The prior covariance matrix deter-
mined the prior model assumptions. The elements of the covariance matrix were chosen such that
the relevant prior model was set (see Appendix 1 for details).
To assess the evidence for interaction between host IFN-l4 variants and viral amino acid site
2414, we used the same Bayesian framework detailed above. The patients were grouped into six
categories based on the host IFN-l4 variants and the presence or absence of serine at viral site
2414. We standardised the log10(viral load) so that it had a mean of zero and standard deviation of
one. We used linear regression to get maximum likelihood estimates of the effects of ‘IFN-l4-Null +
2414 not serine’, ‘IFN-l4-P70 + 2414 not serine’, ‘IFN-l4-P70 + 2414 serine’, ‘IFN-l4-S70 + 2414
not serine’, ‘IFN-l4-S70 + 2414 serine’ groups relative to the ‘IFN-l4-Null + 2414 serine’ group. The
estimates were adjusted for cirrhosis status and population structure including the first two viral PCs
and the first three host PCs in the regression as covariates. The prior covariance matrix determined
the prior model assumptions. The elements of the covariance matrix were chosen such that the rele-
vant prior model was set (see Appendix 1 for details).
Materials and correspondence
Correspondence and material requests should be addressed by contacting STOP-HCV http://www.
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Appendix 1
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Viral principal components association with host IFNL4
SNP rs12979860
The first two viral PCs were clustered with clades on the virus phylogeny (Figure 1—figure
supplement 2a). The other PCs changed more gradually and were grouped to a lesser degree
with specific clades on the tree. To explore any specific role for IFNL4 SNP rs12979860 on viral
diversity, we tested whether any viral PCs were associated with SNP rs12979860 genotypes in
a univariate analysis and observed that the fifth and seventh PCs were associated with IFNL4
SNP rs12979860 genotypes (Figure 1—figure supplement 2b–d) respectively explaining 0.7%
and 0.5% of the total variance in the nucleotide sequences (Figure 1—figure supplement 1b).
To investigate whether the observed associations between IFNL4 SNP rs12979860
genotypes and viral PCs were due to host-virus population co-structuring, we selected 500
SNPs across the human genome with frequencies similar to the IFNL4 SNP rs12979860 SNP
and tested for association between these SNPs and the viral PCs (Figure 1—figure
supplement 2b). If host-virus populations co-structuring was responsible for the observed
association between viral PCs and host IFNL4 SNP rs12979860 genotypes, we would expect
these 500 SNPs to also correlate with fifth and seventh viral PCs. At a 10% FDR, none of the
viral PCs were associated with any of the 500 frequency-matched SNPs. Overall, these results
indicate that the observed association between IFNL4 SNP rs12979860 genotypes and the two
viral PCs is a consequence of biological interaction between the IFNL4 locus and the virus
sequences and not due to population structure or other systematic bias.
Amino acids associated with IFNL4 SNP rs12979860
genotypes within the viral protein E2
Twenty-six of the 76 sites (34%) associated with the IFNL4 locus at 10% FDR lie within the E2
glycoprotein that is involved in virus entry and directly interacts with two critical cell surface
receptors, CD81 and SR-BI. Almost half of these IFN-l4-associated residues are present in the
solved E2 core structure. Interestingly, each of these amino acids is located on the surface of
E2 (Figure 1—figure supplement 5) (Kong et al., 2013). Residues 438, 442, 521, 524 and 546
lie on the neutralizing face of E2; four are in regions targeted by neutralizing antibodies known
as Epitope II (aa436-446) and Epitope III (aa523-549), which contain CD81-receptor binding
residues. Five residues 576, 576d, 577, 578 and 580 are located within the intergenotypic
variable region (igVR) that has a role in virion assembly (Albecka et al., 2011;
McCaffrey et al., 2011). Recent evidence suggests that the igVR is under strong selective
pressure during infection and that it may function to modulate exposure of both the CD81
binding region and antibody epitopes on the surface (Alhammad et al., 2015). This is
supported by a study where mutation of igVR residues to alanine reduced binding of non-
neutralizing antibodies (Pierce et al., 2016). For sites that are not present in the structure,
eight lie within hypervariable region 1 (HVR1) (aa384-411), an immunodominant region of E2,
and two are in hypervariable region 2 (HVR2) (aa474-482). Residue 399 in the HVR1 has been
implicated in receptor interaction with SR-BI and heparan sulphate (Dao Thi et al., 2011;
Bartosch et al., 2005). Remarkably, residues 457, 500, 501, 558 and 662 have all been shown
to modulate the presentation of antibody epitopes as mutation to alanine altered antibody
binding (Pierce et al., 2016). Residue 741 lies within the transmembrane domain (718-742).
While it is well-documented that type I IFNs can impact the B-cell response via direct and
indirect mechanisms, there is little information regarding any influence by type III IFNs.
Crucially, it has been shown that both naı¨ve and memory B cells express the IFN-l1
receptor (de Groen et al., 2015). Furthermore, there is evidence that type III interferon can
influence antibody production (de Groen et al., 2015; Egli et al., 2014a). Together, our
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analysis suggests that IFNL4 may exert selection pressure on E2 modulating the structure such
that presentation of receptor binding sites and antibody epitopes are altered.
Viral dinucleotide frequencies in BOSON and EAP cohorts
and their association with IFNL4 SNP rs12979860.
To investigate how IFNL4 impacts on viral sequences, we estimated the dinucleotide
frequencies for each HCV sequence in the different IFNL4 SNP rs12979860 groups (CC vs.
non-CC, Figure 1—figure supplements 7 and 8) in the two cohorts. In the BOSON cohort,
the UpA dinucleotide frequency (estimated as the ratio of the observed to expected
frequency) was significantly lower in the IFNL4 non-CC group compared to the CC group
(p=2.710 6) using linear regression adjusting for two viral PCs and three host PCs. On the
contrary, the UpG dinucleotide frequency was significantly higher in the IFNL4 non-CC group
compared to the CC group (p=2.310 5). The CpC and CpA dinucleotide frequencies were
also significantly different between the IFNL4 genotypes (CC vs. non-CC) using a Bonferroni
correction for multiple testing (p<0.003). In the EAP cohort, the same trend, although not
significant, was observed for the UpA and UpG dinucleotide frequencies.
Bayesian model comparison for genetic effect sizes on
viral load
We used approximate Bayes factors (ABFs) to estimate the posterior probability of each
model of genetic association as described in Band et al. (2013). The ABF differs from the
Bayes Factor in that it depends on a normal approximation of the regression likelihood (up to
a constant) as suggested by Wakefield (2007). For each model of association we assume a
prior on the effect size which is normally distributed around zero. By changing the prior
covariance (or correlation) of effect sizes we can formally compare models. The ABF for each
model is calculated as the ratio of the approximate marginal likelihood of that model to that
of the null model where all the prior weight is on an effect size of zero; note that the ABF for
the null model is then equal to 1. Under the assumption that exactly one of the models is
correct and all models are equally likely a priori, the posterior probability of a given model is
calculated as the ABF for that model divided by the sum of the ABFs for all models under
consideration.
Calculation of the marginal likelihood requires specification of a prior distribution for the
effects as well as maximum likelihood (ML) point estimates of these effects with their
asymptotic standard errors. As a concrete example, let us use the IFN-l4 variants effects on
viral load. Using a linear regression we estimate the two effect sizes for IFN-l4-P70 and IFN-l
4-S70 relative to the IFN-l4-Null variant and their asymptomatic standard error. These
estimates are adjusted for cirrhosis status and population structure by including the fist two
viral PCs and the first three host PCs. We then define the covariance prior matrix which in this
case is a 2  2 matrix indicating the correlation and variances of effect sizes of IFN-l4-S70 and
IFN-l4-P70 relative to the IFN-l4-Null variant. The five tested models and their priors are as
follows:
1) Both IFN-l4-S70 and IFN-l4-P70 have effect sizes of zero (their effects on viral load are
identical to the IFN-l4-Null variant).
S1 ¼
0 0
0 0
 
2) IFN-l4-S70 has an independent effect and IFN-l4-P70 has an effect size of zero (the
effect on viral load is the same as the IFN-l4-Null variant).
S2 ¼
1 0
0 0
 
3) IFN-l4-S70 has an effect size of zero (the effect on viral load is the same as the IFN-l4-
Null variant) and IFN-l4-P70 has an independent effect size.
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S3 ¼
0 0
0 1
 
4) Both IFN-l4-S70 and IFN-l4-P70 have independent effect sizes (their effect on viral load
are different from the IFN-l4-Null variant and different from each other).
S4 ¼
1 0
0 1
 
5) Both IFN-l4-S70 and IFN-l4-P70 have independent and identical effect sizes (their
effects on viral load are the same but different from the IFN-l4-Null variant).
S5 ¼
1 1
1 1
 
The approximate marginal likelihood for any given choice of the prior model is then the
value of the multivariate normal density at the ML estimate:
MVN
b^1
b^2
 
;
0
0
 
;
ccSE
2
b1
0
0 SE
2
b2
" #
þ Si
 !
To investigate the interaction between IFNL4 genotypes (CC vs. non-CC), viral load and site
2414 in the NS5A viral protein, we used the Bayesian approach detailed above. We divided
the patients into six groups (the three variants of IFN-l4 and presence or absence of serine at
viral site 2414). We then fitted a linear regression with standardised log10(viral load) as the
response variable and a categorical variable with the six levels as the explanatory variable. Five
effect sizes and their standard error were estimated for the groups ‘IFN-l4-Null + 2414 not
serine’, ‘IFN-l4-P70 + 2414 not serine’, ‘IFN-l4-P70 + 2414 serine’, ‘IFN-l4-S70 + 2414 not
serine’, ‘IFN-l4-S70 + 2414 serine’ relative to the ‘IFN-l4-Null + 2414 serine’ group. We then
used the prior covariance matrix (a 5  5 matrix) to define 58 models of association (from all
effect sizes being zero to all being different). The posterior probability for each model was
estimated as described above. Model five, where only the ‘IFN-l4-P70 + 2414 serine’ group
had an effect size different from the other groups was the most supported (posterior
probability = 0.33). Twelve other models had posterior probabilities greater than their prior
probabilities. In all these models, the ‘IFN-l4-P70 + 2414 serine’ group had an effect size
different from the base group. The marginal posterior probability of all the models in which
the effect size of group ‘IFN-l4-P70 + 2414 serine’ is different from the ‘IFN-l4-P70 + 2414
not serine’ is 0.98. Furthermore the marginal posterior probability of all the models in which
the effect size of the ‘IFN-l4-P70 + 2414 serine’ is different from the ‘IFN-l4-S70 + 2414
serine’ is 0.97.
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